CN110787202A - Wind-dispelling and collateral-activating oil - Google Patents
Wind-dispelling and collateral-activating oil Download PDFInfo
- Publication number
- CN110787202A CN110787202A CN201911215798.0A CN201911215798A CN110787202A CN 110787202 A CN110787202 A CN 110787202A CN 201911215798 A CN201911215798 A CN 201911215798A CN 110787202 A CN110787202 A CN 110787202A
- Authority
- CN
- China
- Prior art keywords
- wind
- collateral
- oil
- dispelling
- activating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dispersion Chemistry (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The embodiment of the invention discloses a wind-dispelling and collateral-activating oil, and belongs to the technical field of medicines. The wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 10-45% of folium artemisiae argyi essential oil, 5-30% of menthol, 5-25% of methyl salicylate and 0.5-2% of eugenol. The wind-dispelling and collateral-activating oil disclosed by the invention takes the argy wormwood leaf essential oil, the menthol, the methyl salicylate and the eugenol as raw materials, has the effects of dispelling wind, activating collaterals, relaxing tendons and relieving pain, has an exact curative effect on preventing and treating the attack of acute rheumatic arthritis or gouty arthritis, can be used timely and properly to enable the reversion of the state of an illness to be stopped, thereby avoiding the generation of pain, and has a wide application prospect.
Description
Technical Field
The embodiment of the invention relates to the technical field of medicines, and particularly relates to a wind-dispelling and collateral-activating oil.
Background
Acute rheumatic arthritis is marked by red, swollen, hot and painful large joints, is migratory and has recurrent attacks. Gouty arthritis is one of common rheumatism, and a series of clinical syndromes mainly comprise red, swollen, hot, painful and pressure pain of affected joints due to deposition of urate which is a final product of purine metabolism in tissues.
The preparation for controlling the pain attack caused by acute rheumatic arthritis and gouty arthritis on the market comprises two parts of pure chemical synthetic medicine and Chinese patent medicine. Pure chemical synthetic drugs such as naproxen, ibuprofen, sertraline and the like can obviously relieve pain symptoms, but can not fundamentally relieve the cause of disease, can not prevent the development of the course of disease and control the relapse of disease, and simultaneously have obvious side effects, and are extremely unfavorable for the health after long-term use.
The Chinese patent medicine comprises domestic and domestic strong prescription wind-dispelling and collateral-activating pills such as Chenlaodi wind-dispelling and collateral-activating pills and imported strong prescription wind-dispelling and collateral-activating pills produced from Germany, is a strong-effect treatment preparation for resisting acute rheumatic arthritis and gouty arthritis at present, has the advantage of small side effect compared with pure chemically synthesized medicines, but has long administration time and long treatment time and indefinite effect on stimulation and damage of the stomach due to excessive components.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
Therefore, the embodiment of the invention provides the wind-dispelling and collateral-activating oil, which is used for solving the problems of lack of targeting and great side effect of the existing pure chemical synthetic medicine, and difficult avoidance of stomach stimulation and damage caused by slow effect taking and long taking time of Chinese patent medicines.
The inventor of the application is a medical practitioner engaged in pharmaceutical research for more than thirty years, and is also an individual with a rheumatism hereditary family history, and the family of people all have a medical history of disease incidence after the middle-aged, the inventor is not exceptional, and the large and small joints of the body are suffered from pain after the fifties, and the patients are eaten by pure chemical synthetic drugs and traditional Chinese medicines, and the ancient and imported medicines are also used, so that the effect is not ideal. After reviewing a large number of medical prescriptions and modern scientific and technical literatures about rheumatic meridians, the inventor develops a wind-expelling and collateral-activating agent which can prevent or eliminate arthralgia caused by acute rheumatic arthritis or gouty arthritis, and has obvious effect through clinical application.
In order to achieve the above object, the embodiments of the present invention provide the following technical solutions:
according to a first aspect of the embodiments of the present invention, an embodiment of the present invention provides a wind-driving collateral-activating oil, which includes the following components by weight: 10-45% of folium artemisiae argyi essential oil, 5-30% of menthol, 5-25% of methyl salicylate and 0.5-2% of eugenol.
In a preferred embodiment, the wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 25-40% of folium artemisiae argyi essential oil, 20-25% of menthol, 15-20% of methyl salicylate and 1-2% of eugenol.
In a preferred embodiment, the wind-dispelling and collateral-activating oil further comprises 10-30 wt% of liquid paraffin and 0.5-3 wt% of turpentine.
In a preferred embodiment, the wind-dispelling and collateral-activating oil further comprises 23-30 wt% of liquid paraffin and 1-2 wt% of turpentine.
In a preferred embodiment, the wind-dispelling and collateral-activating oil further comprises a lubricant, an antibacterial agent or an oil-soluble pigment in order to improve the appearance of the product, make the product fine, obtain good skin feeling when in use, prolong the shelf life of the product, and the like.
According to a second aspect of the embodiments of the present invention, the embodiments of the present invention provide an application of the wind-dispelling and collateral-activating oil described above in preparing a medicament for preventing or treating acute rheumatic arthritis or gouty arthritis.
The preparation method of the wind-dispelling and collateral-activating oil is a conventional method in the field.
And (3) argy wormwood leaf essential oil: the folium artemisiae argyi has specific medicinal active substances and has the effects of relieving cough and asthma, diminishing inflammation, relieving pain, clearing heat and the like.
Menthol: white crystal extracted from leaf and stem of herba Menthae, and its molecular formula C10H20O, is the main component in peppermint and peppermint essential oils. It can be used as irritant in medicine, and has effects in refreshing and relieving itching; can be taken orally as a wind-expelling medicine for treating headache and nose; pharynx; laryngitis and the like.
Methyl salicylate: has local stimulating effect, and can promote local blood circulation, and topical or topical application can produce skin vasodilatation, red skin, and reflex influence on skin, muscle, nerve and joint of corresponding parts, and has repercussive, antiinflammatory and analgesic effects, and also has antipruritic effect. Can be used for treating sprain, contused wound, lumbago, myalgia, neuralgia, and antipruritic.
Eugenol: has antiinflammatory, analgesic, and antibacterial effects.
The traditional Chinese medicine says that pain is caused by obstruction of qi and blood and pain is caused by excessive wind and dampness regardless of arthritis or gout. The solution to this problem is to solve the two problems of expelling wind and dredging the channels first. The menthol is selected for dispelling wind, and has the effect of dispelling wind due to strong irritation; the essential oil (about normal 1/60) with extremely small molecular weight extracted from folium artemisiae argyi has the function of dredging twelve meridians, can follow the meridians by virtue of certain stimulation, stimulates the meridian qi and regulates the channels, thereby playing the function of dredging collaterals of promoting qi and blood circulation; the methyl salicylate extracted and processed from the wintergreen oil has the function of local stimulation and can promote local blood circulation, and the local inunction can generate cutaneous vasodilatation and reflectively influence the skin, muscle nerves and joints of corresponding parts to be beneficial to the absorption of essential oil; eugenol has anti-inflammatory and analgesic effects. The adjuvant oleum Terebinthinae has effects of promoting topical blood circulation and relieving pain. The auxiliary material liquid paraffin has the function of assisting dissolution.
The embodiment of the invention has the following advantages:
the wind-dispelling and collateral-activating oil disclosed by the invention takes the argy wormwood leaf essential oil, the menthol, the methyl salicylate and the eugenol as raw materials, has the effects of dispelling wind, activating collaterals, relaxing tendons and relieving pain, can be used for preventing and treating the attack of acute rheumatic arthritis or gouty arthritis in time and properly, and can be used for reversing and stopping the state of an illness, so that the generation of pain is avoided, and the application prospect is wide.
Detailed Description
The present invention is described in terms of particular embodiments, other advantages and features of the invention will become apparent to those skilled in the art from the following disclosure, and it is to be understood that the described embodiments are merely exemplary of the invention and that it is not intended to limit the invention to the particular embodiments disclosed. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The examples do not show the specific techniques or conditions, according to the technical or conditions described in the literature in the field, or according to the product specifications. The reagents or instruments used are conventional products available from regular distributors, not indicated by the manufacturer.
Example 1
The wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 44.2 percent of argy wormwood leaf essential oil, 5.8 percent of menthol, 16.8 percent of methyl salicylate, 1.2 percent of eugenol, 28.4 percent of liquid paraffin, 1.1 percent of turpentine and 2.5 percent of oil-soluble edible pigment.
Example 2
The wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 28.2 percent of argy wormwood leaf essential oil, 27.5 percent of menthol, 16.8 percent of methyl salicylate, 1.8 percent of eugenol, 20.5 percent of liquid paraffin, 1.8 percent of turpentine and 3.4 percent of oil-soluble edible pigment.
Example 3
The wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 28.6 percent of argyi leaf essential oil, 22.9 percent of menthol, 17.2 percent of methyl salicylate, 1.8 percent of eugenol, 27.0 percent of liquid paraffin, 1.8 percent of turpentine and 0.7 percent of oil-soluble edible pigment.
Example 4
The wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 17.5 percent of argy wormwood leaf essential oil, 29.5 percent of menthol, 22.5 percent of methyl salicylate, 1.5 percent of eugenol, 25.2 percent of liquid paraffin, 0.8 percent of turpentine and 3 percent of oil-soluble edible pigment.
Example 5
The wind-dispelling and collateral-activating oil comprises the following components in percentage by weight: 38.5 percent of argy wormwood leaf essential oil, 20.5 percent of menthol, 24.1 percent of methyl salicylate, 0.6 percent of eugenol, 12.8 percent of liquid paraffin, 2.2 percent of turpentine and 1.3 percent of oil-soluble edible pigment.
Comparative example 1
The wind-expelling collateral-activating oil of this comparative example is different from example 1 only in that the equivalent amount of perilla extract is used instead of artemisia argyi essential oil.
Example 6
Patients with confirmed diagnosis of acute rheumatoid arthritis and gouty arthritis were selected as study subjects, all patients volunteered to participate in this trial and received no other treatment for 2 weeks prior to treatment. Patients were randomized into treatment groups 1-5 and control groups.
Treatment 1 group: 18 men and 10 women with the age of 40-67 years are suffering from acute rheumatic arthritis; 23 cases of patients with gouty arthritis and 15 cases of women with the age of 25-60 years.
Treatment 2 groups: 22 men and 13 women with the age of 45-60 years are suffered from acute rheumatic arthritis; 20 male patients and 14 female patients with gouty arthritis are 28-55 years old.
Treatment 3 groups: 25 men and 10 women with the age of 40-66 years of acute rheumatic arthritis patients; the patients with gouty arthritis have 18 men and 12 women, and the ages of the patients are 26-58 years old.
Treatment 4 groups: 24 men and 15 women with the age of 48-70 years are suffered from acute rheumatic arthritis; 28 men and 10 women with gouty arthritis are aged 22-50 years.
Treatment of 5 groups: 20 men and 16 women with the age of 42-70 years are suffering from acute rheumatic arthritis; 23 male patients and 12 female patients with gouty arthritis are 25-52 years old.
Control group: 20 men and 17 women with the age of 42-65 years of acute rheumatic arthritis patients; 28 men and 11 women with gouty arthritis aged 28-60 years.
The patients have no significant difference (P > 0.05) in general data such as age, sex and the like and are comparable.
The patients in the treatment groups 1-5 and the control group respectively use the wind-dispelling and collateral-activating oils of examples 1-5 and comparative example 1, and the use method comprises the following steps: the composition can be applied to affected part for 2 times per day. The patients in both control and treatment groups were treated for 4 weeks.
The criteria for efficacy assessment are as follows:
after 4 weeks of treatment, the patients were observed to have improved symptoms, and the patients had mild, moderate and severe arthralgia and joint mobility scored 1, 2 and 3 points, respectively, and had no joint pain and mobility change scored 0 point.
The effect is shown: the integral of the main symptoms is reduced by more than 70 percent, the joint function is basically recovered to be normal, the normal life and work can be realized, the main biochemical examination indexes are basically normal, and no acute attack occurs.
The method has the following advantages: the integral of the main symptoms is reduced by 40-70%, the joint function is obviously improved, the life and the work are basically self-care, and the main biochemical indexes are obviously improved.
And (4) invalidation: the integral of the main symptoms is reduced by less than 40 percent, or the main symptoms are repeatedly attacked, the medicine can not be controlled, the joint function is not obviously improved, and the main biochemical index is not obviously improved. The total effective rate is (number of effective people + number of effective people)/total number of people.
The results of comparing the clinical efficacy of the treatment group and the control group are shown in Table 1.
TABLE 1
| Group of | n | Show effect | Is effective | Invalidation | Total effective rate |
| Treatment 1 group | 66 | 28 | 32 | 6 | 90.9％ |
| Treatment of 2 groups | 69 | 29 | 35 | 5 | 92.8％ |
| Treatment of 3 groups | 65 | 32 | 30 | 3 | 95.4％ |
| Treatment of 4 groups | 77 | 30 | 41 | 6 | 92.2％ |
| Treatment of 5 groups | 71 | 28 | 39 | 4 | 94.4％ |
| Control group | 76 | 20 | 35 | 21 | 72.4％ |
The results show that the total clinical treatment effective rate of treating the patients in the groups 1 to 5 is obviously higher than that of the control group, and the data difference has statistical significance (P is less than 0.05), so that the wind-dispelling and collateral-activating oil disclosed by the embodiment of the invention has excellent treatment effect on preventing and treating the attack of acute rheumatic arthritis or gouty arthritis.
Although the invention has been described in detail above with reference to a general description and specific examples, it will be apparent to one skilled in the art that modifications or improvements may be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (6)
1. The wind-dispelling and collateral-activating oil is characterized by comprising the following components in percentage by weight: 10-45% of folium artemisiae argyi essential oil, 5-30% of menthol, 5-25% of methyl salicylate and 0.5-2% of eugenol.
2. The wind-driving collateral-activating oil according to claim 1, wherein the wind-driving collateral-activating oil comprises the following components in percentage by weight: 25-40% of folium artemisiae argyi essential oil, 20-25% of menthol, 15-20% of methyl salicylate and 1-2% of eugenol.
3. The wind-driving collateral-activating oil of claim 1, further comprising 10-30% by weight of liquid paraffin and 0.5-3% by weight of turpentine.
4. The wind-driving collateral-activating oil of claim 1, further comprising 23-30% by weight of liquid paraffin and 1-2% by weight of turpentine.
5. The wind-driving collateral-activating oil of claim 1, further comprising a lubricant, an antibacterial agent or an oil-soluble pigment.
6. Use of the wind-expelling collateral-activating oil according to any one of claims 1 to 5 in the preparation of a medicament for preventing or treating acute rheumatic arthritis or gouty arthritis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911215798.0A CN110787202A (en) | 2019-12-02 | 2019-12-02 | Wind-dispelling and collateral-activating oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911215798.0A CN110787202A (en) | 2019-12-02 | 2019-12-02 | Wind-dispelling and collateral-activating oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110787202A true CN110787202A (en) | 2020-02-14 |
Family
ID=69447328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911215798.0A Pending CN110787202A (en) | 2019-12-02 | 2019-12-02 | Wind-dispelling and collateral-activating oil |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110787202A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643590A (en) * | 2020-05-09 | 2020-09-11 | 天津芸熙生物技术有限公司 | Collateral activating oil and preparation method thereof |
| CN112386650A (en) * | 2020-12-15 | 2021-02-23 | 湖北中新药业有限公司 | Essential oil for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof |
| CN112516186A (en) * | 2020-12-08 | 2021-03-19 | 暨南大学 | Application of folium artemisiae argyi volatile oil in inhibiting activation of NLRP3 inflammatory corpuscle |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982322A (en) * | 2017-12-27 | 2018-05-04 | 高宗保 | Ox itch mite spray and preparation method thereof |
-
2019
- 2019-12-02 CN CN201911215798.0A patent/CN110787202A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107982322A (en) * | 2017-12-27 | 2018-05-04 | 高宗保 | Ox itch mite spray and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 刘智斌: "《推拿手法学》", 31 July 2019, 上海科学技术出版社 * |
| 李冈荣: "《800种中草药彩色图鉴：白金珍藏版》", 31 January 2017, 福建科学技术出版社 * |
| 梅全喜: "《艾叶的研究与应用》", 31 October 2013, 中国中医药出版社 * |
| 琚玮: "《新全实用中成药手册》", 30 June 2004, 河南科学技术出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111643590A (en) * | 2020-05-09 | 2020-09-11 | 天津芸熙生物技术有限公司 | Collateral activating oil and preparation method thereof |
| CN111643590B (en) * | 2020-05-09 | 2022-02-25 | 天津芸熙生物技术有限公司 | Collateral activating oil and preparation method thereof |
| CN112516186A (en) * | 2020-12-08 | 2021-03-19 | 暨南大学 | Application of folium artemisiae argyi volatile oil in inhibiting activation of NLRP3 inflammatory corpuscle |
| CN112386650A (en) * | 2020-12-15 | 2021-02-23 | 湖北中新药业有限公司 | Essential oil for treating rheumatic arthritis and rheumatoid arthritis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110787202A (en) | Wind-dispelling and collateral-activating oil | |
| CN102949502B (en) | Scalp folliculitis treatment external application traditional Chinese medicine | |
| CN106619987A (en) | Externally-applied agent for prevention and treatment of pruritus and eczema at female sensitive position | |
| CN105012487B (en) | Children's nose, which relaxes, leads to nasal drops | |
| CN101773518A (en) | Medicine for treating infectious diseases | |
| CN100348239C (en) | Traditional Chinese medicine preparation for treating soft tissue pain and preparation method | |
| WO2016180119A1 (en) | Topical preparation and the use thereof in preparing drugs for treating lumbar disc herniation | |
| CN111920883A (en) | External preparation for treating herpes zoster and preparation method thereof | |
| CN104547825A (en) | Traditional Chinese medicine composition for treating neuromuscular pain and preparation method of preparation of traditional Chinese medicine composition | |
| CN107929338A (en) | The new application of Pien Tze Huang and its preparation in the medicine for preparing treatment post-herpetic neuralgia | |
| CN103341100A (en) | Medicinal liquor for activating blood, relieving pain, resisting inflammation and diminishing swelling | |
| CN108578549B (en) | Medicine for treating acne and application thereof | |
| CN113491739B (en) | Pain-relieving and stasis-eliminating traditional Chinese medicine for treating endometriosis and preparation method thereof | |
| CN112603958B (en) | Traditional Chinese medicine composition for treating myofascitis and preparation method and application thereof | |
| CN101979056A (en) | Traditional Chinese medicament for treating asthma | |
| CN101337006B (en) | Compound liniment for treating acne | |
| CN107029072A (en) | A kind of Hibisci Paste with antiinflammatory action | |
| CN106729213B (en) | Compound traditional Chinese medicine for treating rheumatoid arthritis in acute stage and application thereof | |
| CN106729427B (en) | External traditional Chinese medicine composition for treating wind-damp-cold arthralgia, using method and application thereof | |
| CN104906379A (en) | Traditional Chinese medicine ointment for treating bullous impetigo and preparation method of ointment | |
| CN106309926A (en) | Composition prepared from bee products and medical and edible dual-purpose food and used for treating gastritis and gastric ulcer | |
| CN102988472B (en) | Traditional Chinese medicine external-use embrocation for treating acne rosacea | |
| CN104906217A (en) | Traditional Chinese medicine ointment for treating acute catarrhal conjunctivitis and preparation method thereof | |
| CN111939196A (en) | Essential oil pain relieving ointment for relieving gout | |
| CN114288374A (en) | Herbaceous plant preparation for treating blood stasis type cervical and lumbar diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200214 |
|
| RJ01 | Rejection of invention patent application after publication |